Neoplasms

All Conditions

Symptoms and General Pathology

Digestive System Diseases

Carcinoma

Neoplasm Metastasis

Colorectal Neoplasms

Neoplasms, Second Primary

Liver Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Neoplastic Processes

Liver Diseases

Hematinics

All Drugs and Chemicals

Micronutrients

Antineoplastic Agents

Vitamins

Liver Extracts

Leucovorin

Fluorouracil

Oxaliplatin

Antibodies

Antibodies, Monoclonal

Immunoglobulins

Antimetabolites

Immunosuppressive Agents

Immunologic Factors

Antidotes

Protective Agents

Folic Acid

Vitamin B Complex

Trace Elements

Folate

Vitamin B9

Adecatumumab,6-9mg/kg, every 14 days, 24 cycles

Adecatumumab

FOLFOX 4, every 14 days, 12 cycles followed by Adecatumumab, 6-9mg/kg, every 14 days, 12 cycles

Adecatumumab and FOLFOX

FOLFOX 4

Peter Neuhaus, Prof. Dr.

Patrick Dufour, Pr. Dr.

The purpose of this study is to determine the effect of adecatumumab alone or following FOLFOX in patients with R0 resected liver metastases from CRC (colorectal carcinoma) and to compare the effect to FOLFOX alone.

Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases

A Randomized, Open-label, Controlled, Multi-center Phase II Study to Evaluate the Efficacy and Safety of Adecatumumab Alone or Sequentially to FOLFOX Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases

Amgen Research (Munich) GmbH

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases	NCT00866944	Liver Metastase... Colorectal Canc...	Adecatumumab Adecatumumab an... FOLFOX 4	18 Years -	Amgen Research (Munich) GmbH
Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases	NCT00866944	Liver Metastase... Colorectal Canc...	Adecatumumab Adecatumumab an... FOLFOX 4	18 Years -	Amgen Research (Munich) GmbH

Spots Global Cancer Trial Database for adecatumumab

Every month we try and update this database with for adecatumumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.